Despite Months of Private Engagement From Irenic and Presumably Other Investors, Chairman CEO Rick E. Winningham and Theravance's Board Refuse to Act in Shareholders' Best Interests Notes Theravance's
Theravance Biopharma (TBPH) Issues Update for 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Strategic priorities focused on continued Net Sales growth for YUPELRI® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS) in Multiple.
Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35%.
Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date1: $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine.